Answers are grounded in this paper and cite their sources.
Pharmacists and managed care professionals Activity OverviewIron deficiency anemia (IDA) is closely linked to inflammatory bowel disease (IBD).Treatment often consists of iron replacement therapy, and novel intravenous (IV) iron formulations have impacted the management of patients with both IBD and IDA.Managed care professionals must understand the role of IV iron in treating patients with IBD and IDA, as well as safety and efficacy considerations.This activity will review the role of IV iron replacement in IBD and IDA and focus on the economic burden of these disease states and the impact of IV iron on healthcare resource use. Statement of Educational NeedInflammation in the gastrointestinal tract can result in iron deficiency anemia (IDA), which is the most common complication of inflammatory bowel disease (IBD).Treatment options for IBD can also contribute to the condition, with between 36% and 90% of patients with IBD developing IDA.These patients experience higher rates of hospitalization, longer lengths of stay, and high healthcare costs.Managed care professionals should be familiar with newer intravenous (IV) iron replacement therapies that are entering the treatment landscape of iron deficiency in IBD with the potential to reduce healthcare resource utilization and lessen disease severity for patients.The market for IV iron is expected to increase considerably through 2026, and payers must be equipped to address challenges affecting utilization of and access to these therapies, such as ensuring access to infusions when products require higher doses.To appropriately individualize the treatment of IDA in patients with IBD, managed care professionals must recognize the indications, risks, and benefits of IV iron replacement therapies to develop and implement evidence-based pathways and management plans. Educational ObjectivesUpon completion of this activity, participants should be able to: • Examine the biologic pathways relevant to iron hemostasis in inflammatory bowel disease (IBD) as well as appropriate monitoring of iron status.• Compare iron replacement therapies, including risks and benefits, for the treatment of patients with IBD and iron deficiency.• Explore the health-related quality of life and economic burden of iron deficiency anemia in relation to the evolving evidence-based treatment protocols for patients with IBD and iron deficiency to improve outcomes and efficiently allocate healthcare resources. Accreditation StatementPharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.This activity is approved for 2.0 contact hours (0.20 CEU) under the ACPE universal activity number 0290-0000-21-265-H01-P.The activity is available for CE credit through July 15, 2022.
No takes yet. Share an insight, caveat, or question.
Nicole Bohm (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: